Abstract
The cytostatic and antimetastatic activities of 1,2-di(3,5-dioxopiperazin-1-yl) propane (ICRF-159, razoxane) were studied in a transplantable, slowly growing osteosarcoma in Sprague-Dawley rats. This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
Early treatment with razoxane (30 mg/kg i.p. from day −2 to + 14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59·9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3·4 per cent and 26·1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.
Similar content being viewed by others
References
Boggust, W. A., and O'Connel, S., 1980, Changes in cells induced by drugs inhibiting experimental tumour metastasis in mice, by polyamines and by radiation. Excerpta Medica International Congress Series, 484, 374–386.
Boggust, W. A., O'Connell, S., Carroll, R., and Wilson, P., 1980, Inhibition of metastasic tumour development in WHT/HT mice by Putrescine, Spermidine and Spermine administration. IRCS Medical Science: Cancer, 8, 597–598.
Creighton, A. M., Hellmann, K., and Whitecross, S., 1969, Antitumor activity in a series of bisdioxopiperazines. Nature, 222, 384.
Gilbert, J. M., Hellmann, K., Evans, M., Cassell, P. G., Stoodley, B., Ellis, H., and Wastell, C., 1982, Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer. Cancer Chemotherapy and Pharmacology, 8, 293–299.
Hellmann, K., 1984, Razoxane. Clinical Chemotherapy, Vol. III, Antineoplastic Chemotherapy, edited by H. P. Kuemmerle (New York: Thieme-Stratton), pp. 275–282.
Herman, E. U., Witiak, D. T., Hellmann, K., and Waravdekar, V. S., 1982, Biological properties of ICRF-159 and related Bis(dioxopiperazine) compounds. Advances in Pharmacology and Chemotherapy, 19, 249–290.
Kadmon, D., Heston, W. D., and Fair, W. R., 1981, Effect of surgery and adjuvant chemotherapy on the R3327 MAT-LY LU tumor. Prostate, 2, 299–307.
Salsbury, A. J., Burrage, K., and Hellmann, K., 1970, Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic. British Medical Journal, 4, 344–346.
Salsbury, A. J., Burrage, K., and Hellmann, K., 1974, Histological analysis of the antimetastatic effect of (−)-1,2-Bis(3,5-dioxopiperazine-1-yl) propane. Cancer Research, 34, 843–849.
Skolnik, G., Bagge, U., and Hilgard, P., 1985,The effect of a primary tumour and its metastases on the lodgement of circulating tumour cells. Treatment of Metastasis: Problems and Prospects, edited by K. Hellmann and S. A. Eccles (London, Philadelphia: Taylor & Francis), pp. 219–222.
Weber, E., 1982, (Hrsg.) Statistische Auswertung biomedizinischer Daten—Teil II, Survival. Deutsches Krebsforschungszentrum, Heidelberg.
Wingen, F., Schmahl, D., Berger, M. R., and Spring, H., 1984, Intraosseously transplantable osteosarcoma with regularly disseminating pulmonary metastases in rats. Cancer Letters, 23, 201–211.
Wingen, F., and Schmahl, D., 1985,A transplantable osteosarcoma in rats with regular occurrence of lung metastases as a model for chemotherapy. Treatment of Metastasis: Problems and Prospects, edited by K. Hellmannand S. A. Eccles (London, Philadelphia: Taylor & Francis), pp. 107–111.
Wingen, F., and Weber, E., 1987, Changing metastatic patterns of transplantable rat osteosarcoma. Clinical and Fxperimental Metastasis, 5, 17–26.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wingen, F., Spring, H. & Schmähl, D. Antimetastatic effects of razoxane in a rat osteosarcoma model. Clin Exp Metast 5, 9–16 (1987). https://doi.org/10.1007/BF00116621
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00116621